GLENMARK Glenmark Pharmaceuticals Q1 FY27 results (Apr–Jun 2026) and concall
Glenmark Pharmaceuticals reported a strong Q1 FY27 with consolidated revenue growth of 23.1% driven by robust performance across India, North America, and Emerging Markets. The company maintained its gross margin despite geopolitical cost pressures, focusing on product and geographical mix. Strategic launches in oncology and respiratory segments are expected to fuel future growth, while R&D investments continue for its innovative pipeline.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 1.7%, net profit up 123.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,636 | 2,251 | 2,010 | 2,395 | 1,539 −42% | 2,360 +5% | 2,147 +7% | 2,435 +2% |
| EBITDA | 779 | 494 | 341 | 728 | -178 −123% | 496 +0% | 32 −91% | 613 −16% |
| Net profit | 595 | 414 | 148 | 330 | -739 −224% | 282 −32% | -74 −150% | 736 +123% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
